October 20, 2022 PR-M10-22-06
Solution Centers in the United States, Latin America, and Europe reflect the company's commitment to investing in innovation, technology, and expertise in the pharmaceutical ingredients space.
DOWNERS GROVE, Ill /PRNewswire/ -- Univar Solutions Inc. (NYSE: UNVR) ("Univar Solutions" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals, today announced the addition of four pharmaceutical ingredient labs at its flagship Solution Centers in Houston, Texas; Osasco - São Paulo, Brazil; Mexico City, Mexico; and Essen, Germany. The new facilities, designed to foster innovation and growth for customers in life science markets, will provide technical services such as formulation and prototype development, performance and application testing, chemical and product performance analysis, and custom blending for various dosage forms including oral solid dose (OSD), semi-solid, liquid, and topical.
Through its pharmaceutical ingredient labs, Univar Solutions enables suppliers and customers in primary and secondary pharmaceutical segments to better meet regulatory challenges, optimize, and progress drug development. Staffed with pharmaceutical field scientists and equipped with advanced pharmaceutical analytical equipment, these facilities will allow the organization to deliver greater value and responsiveness to market opportunities across life science segments including pharmaceuticals, biopharmaceuticals, animal health, nutraceuticals, and ophthalmic.
"Increasingly, pharmaceutical manufacturers are turning to Univar Solutions for innovation and technical support, plus insights into forthcoming trends and market dynamics. We are very excited to work alongside our strategic suppliers as they look to develop innovative, next-generation solutions that align with our commitment to help keep communities healthy, fed, clean, and safe. By establishing our pharmaceutical ingredient labs in centrally located, growing regions around the world, we have taken a truly globalized approach to supporting the market," said James Peterson, global vice president, Pharmaceutical Ingredients for Univar Solutions.
Through its Solution Centers, Univar Solutions supports customers across the Pharmaceutical Ingredients, Food Ingredients, Beauty & Personal Care, Coatings, Adhesives, Sealants, Elastomers, and Rubber & Plastic Additives, Household & Industrial Cleaning, and Lubricants & Metalworking Fluids industries. Customers and suppliers have access to hundreds of technically trained and experienced professionals globally with local knowledge and specialized industry and application expertise who help solve complex formulation challenges, address changing regulatory requirements, innovate to meet the latest market trends, and support efforts to achieve sustainability and other environmental, social, and governance (ESG) goals.
"Each of our regional flagship Solution Centers carries their own layer of specialty knowledge and skill with forward-thinking experts who remain laser focused on the science and chemistry of each new discovery. These flagship locations allow us to get the first glance at future trends across multiple businesses while leveraging our skill base. The combination of our global labs--and a network of local labs--helps us better serve our customers quickly, efficiently, and robustly," said Dr. Andrew Mint, director of global Solution Centers for Univar Solutions.
Discover more at univarsolutions.com/pharmaceutical-formulation-lab-services.
This press release includes certain statements relating to future events and our intentions, beliefs, expectations, and predictions for the future, which are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are subject to known and unknown risks and uncertainties, many of which may be beyond the Company's control. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from the expectations and assumptions. A detailed discussion of these factors and uncertainties is contained in the Company's filings with the Securities and Exchange Commission. Potential factors that could affect such forward-looking statements include, among others: the ultimate geographic spread of the COVID-19 pandemic; the duration and severity of the COVID-19 pandemic; actions that may be taken by governmental authorities to address or otherwise mitigate the impact of the COVID-19 pandemic; the potential negative impacts of COVID-19 on the global economy and our customers and suppliers; the overall impact of the COVID-19 pandemic on our business, results of operations and financial condition; other fluctuations in general economic conditions, particularly in industrial production and the demands of our customers; significant changes in the business strategies of producers or in the operations of our customers; increased competitive pressures, including as a result of competitor consolidation; significant changes in the pricing, demand and availability of chemicals; our levels of indebtedness, the restrictions imposed by our debt instruments, and our ability to obtain additional financing when needed; the broad spectrum of laws and regulations that we are subject to, including extensive environmental, health and safety laws and regulations; an inability to integrate the business and systems of companies we acquire, including of Nexeo Solutions, Inc., or to realize the anticipated benefits of such acquisitions; potential business disruptions and security breaches, including cybersecurity incidents; an inability to generate sufficient working capital; increases in transportation and fuel costs and changes in our relationship with third party providers; accidents, safety failures, environmental damage, product quality and liability issues and recalls; major or systemic delivery failures involving our distribution network or the products we carry; operational risks for which we may not be adequately insured; ongoing litigation and other legal and regulatory risks; challenges associated with international operations; exposure to interest rate and currency fluctuations; potential impairment of goodwill; liabilities associated with acquisitions, ventures and strategic investments; negative developments affecting our pension plans and multi-employer pensions; labor disruptions associated with the unionized portion of our workforce; and the other factors described in the Company's filings with the Securities and Exchange Commission. We caution you that the forward-looking information presented in this press release is not a guarantee of future events or results, and that actual events or results may differ materially from those made in or suggested by the forward-looking information contained in this press release. In addition, forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "plan," "seek, "will," "expect," "intend," "estimate," "anticipate," "believe" or "continue" or the negative thereof or variations thereon or similar terminology. Any forward-looking information presented herein is made only as of the date of this press release, and the Company does not undertake any obligation to update or revise any forward-looking information to reflect changes in assumptions, the occurrence of unanticipated events, or otherwise, except as required by law.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.